11:44 AM EST - Acerus Pharmaceuticals Corporation : Reported its financial results for the three-month period ended September 30, 2017. Unless otherwise noted, all amounts are in U.S. dollars. Product revenue for Q3 2017 grew to $1.6 million versus $1.4 million for Q3 2016. Adjusted EBITDA were a loss of $0.6 million for the three months ended September 30, 2017 compared to $0.5 million for the three-months ending September 30, 2016. Acerus Pharmaceuticals Corporation
shares T.ASP are trading down $0.005 at $0.12.
